The system is indicated for use to necrotise or coagulate soft tissue using interstitial irradiation or thermal therapy under MRI guidance. Credit: Dmitriy Gutarev / Pixabay.

ClearPoint Neuro has enrolled the first participant in a glioblastoma clinical trial of its laser therapy system at Skåne University Hospital in Lund, Sweden.

Sponsored by Clinical Laserthermia Systems (CLS), the Safety and Feasibility of Magnetic Resonance (MR)-guided Laser Thermal Ablation of Brain Lesions study will evaluate the ClearPoint Prism Neuro Laser Therapy System.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The prospective single-centre, single-arm clinical trial has been designed to assess the feasibility and safety of using the minimally invasive MR-guided system for ablating tumours in up to five patients with glioblastoma.

The ClearPoint Prism Neuro Laser Therapy System has been indicated for use to necrotise or coagulate soft tissue using interstitial irradiation or thermal therapy under the guidance of magnetic resonance imaging (MRI) in neurosurgery.

It includes a clinical solution that combines the ClearPoint navigation platform with a thermal ablation monitoring software, known as Thermoguide, from Image Guided Therapy (IGT), which is based in Bordeaux, France.

The company holds the exclusive global rights for the commercialisation of the system by CLS for neuro applications.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

ClearPoint Neuro president and CEO Joe Burnett said: “We are proud to support SUS Lund and CLS on this pilot study using the innovative laser therapy system to treat glioblastoma lesions.

“The ClearPoint Neuro Navigation System offers an efficient one-room solution that helps neurosurgeons in the United States to accurately place laser fibres and help treat brain tumours, radiation necrosis and epileptic foci in thousands of patients.

“Expanding brain and spine laser therapy treatment options for patients and neurosurgeons in the EU, and beyond, is a key priority in the years ahead.”

CLS will use the data from the glioblastoma clinical trial to seek CE Mark for the system in Europe.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact